Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial

Shen Li, MD, Annette E Hay, Michael Crump, MD, Peter Anglin, MD FRCPC, MBA, Tara Baetz, Ralph Meyer, MDFRCPC, Armand Keating, MD, Sue Robinson, MD, Matthew Seftel, MRCP, MD MPH, FRCPC, Caterina Stelitano, Marina S Djurfeldt, MSc, Lois E. Shepherd, Bingshu E. Chen, Sarit Assouline, MD

Blood (2017) 130 (Supplement 1): 2015.

https://doi.org/10.1182/blood.V130.Suppl_1.2015.2015

Published: 2017

Journal Articles

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

John Kuruvilla, David A. MacDonald, C. Tom Kouroukis, Matthew Cheung, Harold J. Olney, A. Robert Turner, Peter Anglin, Matthew Seftel, Walid Sabry Ismail, Stefano Luminari, Stephen Couban, Tara Baetz, Ralph M. Meyer, Annette E. Hay, Lois Shepherd, Marina S. Djurfeldt, Sameer Alamoudi, Bingshu E. Chen, Michael Crump

Blood (2015) 126 (6): 733–738.

https://doi.org/10.1182/blood-2015-01-622084

Published: 2015

Journal Articles

The ASH Practice Improvement Module in Non-Hodgkin Lymphoma: Assessing the Feasibility, Reliability and Usefulness of a New Quality Improvement Tool

Michael D Jain, PhD MD, Lee Mozessohn, MD, Lauren M Gerard, MD, Jackie Ostro, MD, Mansoor Radwi, MD, Bertrand Routy, MD, Bethany Gill, BSc, MMath, Tony Panzarella, M.Sc., P.Stat., Peter Anglin, MD, Matthew C Cheung, Vishal Kukreti, Lisa Hicks, MD MSc

Blood (2014) 124 (21): 2651.

https://doi.org/10.1182/blood.V124.21.2651.2651

Published: 2014

Journal Articles

Prospective Canadian Trial In Newly Diagnosed Multiple Myeloma Patients with t(4;14): Bortezomib-Based Therapy without ASCT

Donna E. Reece, MD, Giovanni Piza Rodriguez, Andrew Belch, MD, David Szwajcer, MD, FRCP(C), Michael J. Kovacs, MD, FRCPC, Chaim Shustik, MD, Nizar J Bahlis, MD, Darrell J White, MD, Mariela Pantoja, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, Suzanne Trudel, MD, MSC, FRCPC

Blood (2010) 116 (21): 1968.

https://doi.org/10.1182/blood.V116.21.1968.1968

Published: 2010

Journal Articles

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Donna E. Reece, MD, Esther Masih-Khan, PhD, Arooj Khan, Saima Dean, Sharon Fung, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Joseph R. Mikhael, MD, Suzanne Trudel, MD, MSC, FRCPC

Blood (2010) 116 (21): 3055.

https://doi.org/10.1182/blood.V116.21.3055.3055

Published: 2010

Journal Articles

Low Risk of Reactivation of Hepatitis B and Hepatic Injury in Multiple Myeloma (MM) Patients (pts) Undergoing Autologous Stem Cell Transplant (ASCT).

Christine Chen, MD, Young Trieu, MSc, Wei Xu, PhD, Suzanne Trudel, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, Donna E. Reece, MD

Blood (2009) 114 (22): 3345.

https://doi.org/10.1182/blood.V114.22.3345.3345

Published: 2009

Journal Articles

Elderly Multiple Myeloma (MM) Patients (≥70 years) Can Safely Undergo Autologous Stem Cell Transplantation (ASCT) but Have Shorter Overall Survival Than Younger Patients (<70 years).

Carla Borgono, MSc, PhD, Young Trieu, MSc, Wei Xu, PhD, Donna E. Reece, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, Peter Anglin, MD, Christine Chen, MD

Blood (2009) 114 (22): 3409.

https://doi.org/10.1182/blood.V114.22.3409.3409

Published: 2009

Journal Articles

Activity with Thalidomide-Based Therapy Following Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.

Trieu Young, MSc, Chia-Min Chu, Wei Xu, PhD, Peter Anglin, MD, Suzanne Trudel, MD, Donna E. Reece, MD, Christine Chen, MD, Vishal Kukreti, MD, FRCPC

Blood (2009) 114 (22): 3855.

https://doi.org/10.1182/blood.V114.22.3855.3855

Published: 2009

Journal Articles

Bortezomib-Based Therapy, without Stem Cell Transplantation, for Newly Diagnosed Multiple Myeloma Patients with t(4;14).

Donna E. Reece, MD, Giovanni Piza Rodriguez, Andrew Belch, MD, David Szwajcer, MD, Mariela Pantoja, Michael Kovacs, MD, Chaim Shustik, MD, Nizar J Bahlis, MD, Darrell J White, MD, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, A. Keith Stewart, MD, Suzanne Trudel

Blood (2009) 114 (22): 3861.

https://doi.org/10.1182/blood.V114.22.3861.3861

Published: 2009

Journal Articles

Sequencing Novel Agents in Relapsed/Refractory Multiple Myeloma: Use of Bortezomib-Based Therapy After Lenalidomide + Dexamethasone.

Donna E. Reece, MD, Young Trieu, MSc, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Wei Xu, PhD, Peter Anglin, MD, Suzanne Trudel, MD

Blood (2009) 114 (22): 1853.

https://doi.org/10.1182/blood.V114.22.1853.1853

Published: 2009

Journal Articles

Stem Cell Mobilization Capacity Is Not a Predictor of Survival in Multiple Myeloma (MM) After Autologous Stem Cell Transplantation (ASCT).

Gloria Lim, BSc, MSc, MD, Wei Xu, PhD, Trieu Young, MSc, Andrew Winter, BScN, Donna E. Reece, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, Christine Chen, MD

Blood (2009) 114 (22): 2154.

https://doi.org/10.1182/blood.V114.22.2154.2154

Published: 2009

Journal Articles

Prolonged Use of Lenalidomide (≥12 Cycles) for Multiple Myeloma (MM) Is Frequently Affected by Dose-Limiting Thrombocytopenia but Is Associated with Improved Quality of Response and Survival.

Elizabeth Yeboah, H.B.Sc., Esther Masih-Khan, PhD, Christine Massey, Donna E. Reece, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, Christine Chen, MD

Blood (2009) 114 (22): 1866.

https://doi.org/10.1182/blood.V114.22.1866.1866

Published: 2009

Journal Articles

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma.

Donna E. Reece, MD, FRCPC, Esther Masih-Khan, PhD, Arooj Khan, Saima Dean, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Joseph R. Mikhael, MD, Suzanne Trudel

Blood (2009) 114 (22): 1874.

https://doi.org/10.1182/blood.V114.22.1874.1874

Published: 2009

Journal Articles

“Longterm Survival (≥10 years) in Multiple Myeloma (MM) Is Associated with Longer Duration of Therapy and Improved Quality of Response to Novel agents”.

Nastaran Noroozi, MD, Donna E. Reece, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, Kimberly Fernandes, MSC, Christine Chen, MD

Blood (2009) 114 (22): 2793.

https://doi.org/10.1182/blood.V114.22.2793.2793

Published: 2009

Journal Articles

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid ® ) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma.

Donna E. Reece, MD, Esther Masih-Khan, Arooj Khan, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, Joseph R. Mikhael, MD, Suzanne Trudel, MD

Blood (2008) 112 (11): 1723.

https://doi.org/10.1182/blood.V112.11.1723.1723

Published: 2008

Journal Articles

Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion.

Donna E. Reece, MD, Young Trieu, MSc, Hong Chang, MD, Wei Xu, PhD, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Joseph Mikhael, MD

Blood (2008) 112 (11): 1724.

https://doi.org/10.1182/blood.V112.11.1724.1724

Published: 2008

Journal Articles

Steroid Refractoriness, but Not Rapidity of Response, to Induction Therapy Predicts for Outcome Post-Autologous Stem Cell Transplant (ASCT) in Patients (Pts) with Multiple Myeloma (MM)

Anca Prica, MD, Young Trieu, MSc, Wei Xu, PhD, Donna E. Reece, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, Peter Anglin, MD, Christine Chen, MD

Blood (2008) 112 (11): 3315.

https://doi.org/10.1182/blood.V112.11.3315.3315

Published: 2008

Journal Articles

Evaluation of Serum Free Light Chains and Outcome in Multiple Myeloma Patients with an Intact Monoclonal Immunoglobulin Treated with Autologous Stem Cell Transplantation.

Young Trieu, Wei Xu, PhD, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Donna E. Reece, MD

Blood (2008) 112 (11): 3323.

https://doi.org/10.1182/blood.V112.11.3323.3323

Published: 2008

NARROW

Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

The ASH Practice Improvement Module in Non-Hodgkin Lymphoma: Assessing the Feasibility, Reliability and Usefulness of a New Quality Improvement Tool

Prospective Canadian Trial In Newly Diagnosed Multiple Myeloma Patients with t(4;14): Bortezomib-Based Therapy without ASCT

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Low Risk of Reactivation of Hepatitis B and Hepatic Injury in Multiple Myeloma (MM) Patients (pts) Undergoing Autologous Stem Cell Transplant (ASCT).

Elderly Multiple Myeloma (MM) Patients (≥70 years) Can Safely Undergo Autologous Stem Cell Transplantation (ASCT) but Have Shorter Overall Survival Than Younger Patients (<70 years).

Activity with Thalidomide-Based Therapy Following Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.

Bortezomib-Based Therapy, without Stem Cell Transplantation, for Newly Diagnosed Multiple Myeloma Patients with t(4;14).

Sequencing Novel Agents in Relapsed/Refractory Multiple Myeloma: Use of Bortezomib-Based Therapy After Lenalidomide + Dexamethasone.

Stem Cell Mobilization Capacity Is Not a Predictor of Survival in Multiple Myeloma (MM) After Autologous Stem Cell Transplantation (ASCT).

Prolonged Use of Lenalidomide (≥12 Cycles) for Multiple Myeloma (MM) Is Frequently Affected by Dose-Limiting Thrombocytopenia but Is Associated with Improved Quality of Response and Survival.

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma.

“Longterm Survival (≥10 years) in Multiple Myeloma (MM) Is Associated with Longer Duration of Therapy and Improved Quality of Response to Novel agents”.

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid ® ) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma.

Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion.

Steroid Refractoriness, but Not Rapidity of Response, to Induction Therapy Predicts for Outcome Post-Autologous Stem Cell Transplant (ASCT) in Patients (Pts) with Multiple Myeloma (MM)

Evaluation of Serum Free Light Chains and Outcome in Multiple Myeloma Patients with an Intact Monoclonal Immunoglobulin Treated with Autologous Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only